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Abstract 
Although a number of studies have indicated that highly metastatic cells tend to adhere more to target endothelium in vitro than low or 
non-metastatic cells, direct evidence about the correlation between cellular adhesiveness and organ disposition of the cells has not been 
obtained. Using positron emission tomography (PET), we have developed a novel technique that enables the non-invasive detection of the 
real-time tumor cell trafficking. The present study shows the correlation between trafficking of murine large cell lymphoma RAW117 and 
the adhesion properties of the cells in vitro. Cells accumulated in the liver time-dependently, and accumulation of RAW117-H10, liver 
metastatic subline ceils, was more intense than that of RAW117-P, the parental cells, indicating that the metastatic potential is correlated 
with the in vivo accumulation of the cells in the target issue. To examine whether the adhesion properties of the cell membrane determine 
the cell trafficking, we performed PET analysis after altering the adhesion properties on the cell membrane by means of cellular protein 
kinase C modulation, since the modulation of this enzyme is known to alter the surface adhesion molecules, i.e., those of the integrin 
superfamily. The treatment of RAW 117-P with 12-O-tetradecanoylphorbol 13-acetate, which caused augmentation f adhesion to hepatic 
sinusoidal microvessel ndothelial cells (HSE) in vitro, enhanced the hepatic accumulation of the cells in vivo. On the contrary, treatment 
of RAW117-H10 with the protein kinase C inhibitor H-7, 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride, which reduced 
the adhesion activity of the cells to HSE, suppressed their accumulation i the liver, although the suppression was observed only during 
the first 30 min after administration f the cells. These data suggest that the adhesion properties of metastatic lymphoma cells are critical 
for the accumulation of these cells in the target issue. 
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1. Introduction 
Metastasis proceeds in multiple steps: blood-borne 
metastasis is thought to occur via platelet-aggregation, 
adhesion of the metastatic ells to the target endothelial 
cells, and invasion into the extracellular matrix. Escape 
from the immune defense system is also important. We 
recently developed a non-invasive technique using positron 
emission tomography (PET) to determine the real-time 
trafficking of tumor cells in vivo, and observed that cells 
of a highly metastatic subline showed intense accumula- 
tion in the target organ, in a lung metastatic model, rat 
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13762NF mammary adenocarcinoma [1]. This technique is 
useful to evaluate the interaction of characteristic metastatic 
tumor cells with various organs in a living animal without 
affecting in vivo circumstances such as blood flow. 
The lung accumulation of the cells, however, is difficult 
to analyze, however, since the lung is a first-pass tissue 
when the cells are injected intravenously. Therefore, we 
examined cell trafficking using a hepatic metastatic model, 
namely, the parental murine RAW I 17 large cell lymphoma 
of low metastatic potential (RAW1 17-P) and its subline 
having high metastatic potential for the liver (RAWI 17- 
HI0), selected in vivo by Brunson and Nicolson [2], in the 
present study to examine the relationship between organ- 
specific metastasis and interaction of the cells with the 
target organ at the early stage of experimental metastasis. 
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Furthermore, to examine whether the cellular surface 
properties of the tumor cells determine the interaction of 
the cells with the target organ, trafficking of the same kind 
of cells whose surface properties were altered by the 
modulation of intracellular protein kinase C (PKC) was 
monitored, since the modulation of PKC is known to affect 
both metastatic potential and surface molecules, i.e., those 
of the integrin superfamily. 
2. Materials and methods 
2.1. Cell preparation for PET analysis 
RAW117 parental line (RAW117-P) and a variant sub- 
line (RAWII7-H10) sequentially selected ten times in 
vivo for liver colonization were kindly donated by Dr. 
Nicolson of the University of Texas. These cells were 
cultured in high-glucose DMEM supplemented with 5% 
fetal calf serum (JRH Biosciences, Lenexa, KS) under a 
humidified atmosphere of 5% CO 2 in air. The cells were 
labeled with [2-18F]FDG by a modified method described 
previously [1]. In brief, the cells were washed with glu- 
cose-free medium and incubated with [2-18F]FDG for 15 
min at 37°C, since the incorporation of FDG reached a 
plateau at about 15 min as determined by use of [14C]FDG 
(data not shown). After the cells had been washed to 
remove the free [2-18F]FDG by centrifugation at 600 X g 
for 10 min, a single cell suspension was obtained. 
2.2. PET analysis of cell trafficking 
PET studies were performed with an animal PET cam- 
era (Hamamatsu Photonics, Hamamatsu, Japan, HSR-2000) 
Fig. 1. PET images of metastatic lymphoma cell trafficking in vivo. Biodistribution during 30 min after administration f [2-18 F]FDG-labeled RAW117-P 
and RAW117-HI0 was imaged by PET. All images are in a coronal plane with a slice size of 3 mm. For reference to PET images, X-ray CT images of 
lungs, heart, liver, and kidneys of a mouse of similar age are presented in the top panel. Gradation was corrected to be comparable between liver and 
kidney. The image intensities of lungs and heart are 8-fold higher than those of liver and kidney. 
C. Ko ike et a l . /  Biochimica et Biophysica Acta 1238 (1995) 99-106  101 
having an effective slice aperture of 3.25 mm and resolu- 
tion of 2.7 mm. RAW117-P or -H10 cells labeled with 
[2-~SF]FDG (1 • l0  6 cells in 0.2 ml high glucose DMEM, 
555 kBq-925 kBq) were injected via a tail vein into 
10-week-old female Balb/c mice (Japan SLC, Hama- 
matsu, Japan) anesthetized with sodium pentobarbital. The 
emission scan of PET was started immediately after injec- 
tion and performed for 90 min. Before injection of the 
cells, transmission scans were obtained by use of an 18.5 
MBq 68Ge/68Ga ring source for attenuation correction. 
The radioactivity in the form of coincidence gamma pho- 
tons was measured and converted to Bq/cm 3 of tissue 
volume by calibration after correction for decay and atten- 
uation. A time-activity curve was obtained from the mean 
pixel radioactivity in the region of interest (ROI) of the 
composed PET images where ROIs that covered the liver 
image were chosen. The injected ose in each experiment 
was normalized as 740 kBq throughout the whole study. 
Each PET experiment presented in this paper was repeated 
at least twice, and similar results were obtained for those 
repeated experiments; although each figure represents a
typical result obtained from a single experiment. 
After every PET measurement, animals were killed for 
removal of organs and counting of the radioactivity in 
these organs with an auto gamma counter to confirm the 
accumulation of cells in each organ. ROI values of each 
organ correlated with the result of the direct counting of 
the radioactivities in each organ. The viability of remain- 
ing cells after administration f the cells was determined at
2 h after initiation of PET scan by Trypan blue dye 
exclusion and the viability of cells was more than 90% 
throughout the whole experiment. 
2.3. X-ray CT analysis 
Ten-week-old female Balb/c mice were anesthetized 
with sodium pentobarbital nd X-ray CT images were 
obtained. Slice distances were 3.2 mm. 
2.4. Cell adhesion assay 
Hepatic sinusoidal microvessel ndothelial cells (HSE) 
of less than 15 passages, kindly provided by Dr. Nicolson 
of the University of Texas, were seeded in 24-well culture 
dishes (2.10 ~ cells/well) in DME/Ham's F12 medium 
containing bovine endothelial mitogen (Biomedical Tech- 
nologies, Stoughton, MA). RAWll7 cells were fluores- 
cence-labeled by incubation with 30/zM 3'-O-acetyl-2',7'- 
bis(carboxyethyl)-4- or 5-carboxyfluorescein, diace- 
toxymethylester (BCECF-AM, Dojindo Laboratories, Ku- 
mamoto, Japan) for 30 min at 37°C [3]. After the labeled 
cells had been washed with PBS, 5. 10 4 of them were 
added into each well of a 24-well culture dish preseeded 
with HSE. After a 30-min or 1-h incubation, the non-ad- 
herent cells were removed, and adherent cells were lysed 
with 1% Triton X-100. The percentage of adherent cells 
was determined fluorometrically. 
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Fig. 2. Time-activity curves of 18F accumulation in the liver after 
injection of [2-18 F]]FDG-labeled RAW117 cells. Time-activity curves of 
~SF in the liver after injection of [2-18 F]FDG-labeled RAWlI7-P (O) 
and RAW I17-H10 (13) were obtained as described in Materials and 
methods. 
2.5. Modulation of intracellular protein kinase C activity 
For activation of PKC in RAW117-P, the cells were 
treated with 0.162 /xM 12-O-tetradecanoylphorbol 13- 
acetate (TPA, Sigma, St. Louis, MO) for 1 h at 37°C. After 
removal of TPA, the cells were labeled with [2-18F]FDG 
and applied for PET scanning, or cells were labeled with 
BCECF-AM and applied for adhesion assays with HSE. 
For the inactivation of PKC in RAW117-H10, cells were 
treated with 200 /xM 1-(5-isoquinolinesulfonyl)-2-methyl- 
piperazine dihydrochloride (H-7, Biomol Research, Ply- 
40 
30 
c 
o "i 20 
"0 
10 
a 
r / z / z / /  ¢ / / / / / /  
i / / / / /1  
i / / / / / /  / / / / / / /  
r zz1111 
T ¢ / i zz /~ i / z / f i l  ¢ / / / / / /  
¢ l l l l l ~  
I I I I I 1 ~  
Ft~W117-P "rmm~l 
401 
L b 
201 
tf 
--F-* 
# 
T t w m ~ l  RAW117-H10 
Fig. 3. Effect of protein kinase C modulators on RAW117 cell adhesion 
to HSE. (a) RAW117-P cells were treated with 0.162 /xM TPA for 1 h, 
and the amount of fluorescence of cells adhering to HSE was determined 
as described in Materials and methods. (b) RAWI17-H10 cells were 
treated with 200 p.M H-7 for 2 h, and the amount of HSE-associated 
fluorescence was determined. Significant differences are shown in the 
figure: *, P < 0.001 when compared with RAWII7-P; ~,  P < 0.05 
when compared with RAWI17-P; #, P < 0.01 when compared with 
RAW117-HI0. 
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mouth Meeting, PA) for 2 h at 37°C. Then, PET analysis 
and adhesion assay were performed similarly as for TPA- 
treated RAW117 cells. 
3. Results 
3.1. Metastatic tumor cell trafficking determined by PET 
For PET analysis of these cells, the cells were labeled 
with [2-~8F]FDG in vitro and intravenously injected into 
the bloodstream of mice. Fig. 1 shows PET images during 
the first 30 min after injection of the cells. X-ray CT 
images are also shown in the top panel of the figure. 
RAW117-H10 cells accumulated in the liver at a higher 
rate than RAWII7-P cells. Both types of cells accumu- 
lated in the lungs, although the number of retained cells 
decreased rapidly as compared with the retention in the 
liver (data not shown). Fig. 2 indicates the time-activity 
curves of RAW117-P and RAWll7-H10 accumulation i
the liver. The accumulation of RAWll7-H10 was more 
intense than that of RAWI17-P during the PET measure- 
ment, indicating strong interaction of liver metastatic 
RAWII7-H10 cells with liver endothelium in vivo and 
confirming the metastasis of the cells to the liver. 
3.2. Effect of protein kinase C modulators on RA Wl l7 cell 
trafficking 
Recently, PKC was reported to regulate tumor cell 
adhesion to endothelium and extracellular matrix [4-11]. 
Furthermore, integrins were reported to be the substrates 
for both PKC [12,13] and tyrosine kinases [14]. Therefore, 
the trafficking of tumor cells might be altered when PKC 
activity is modulated. So we examined the adhesion of 
RAWI17 cells to HSE in vitro under conditions where 
PKC activity was changed. As shown in Fig. 3, in agree- 
ment with previous observations [15], the rate of adhesion 
of highly metastatic RAW117-H10 cells to HSE was higher 
than that of low metastatic RAW117-P cells. Furthermore, 
adhesion of RAW117-P to HSE was increased more than 
70% by treatment with TPA. Adhesion of RAW117-H10 
to HSE was suppressed to nearly 50% after treatment with 
H-7. These observations suggest hat PKC activity is re- 
lated to the adhesion of RAW117 cells to HSE. 
Subsequently, we investigated in vivo the trafficking of 
RAW117 cells after modulating PKC activities. Fig. 4 
shows the PET images of hepatic accumulation of 
RAW117-P cells with or without TPA treatment. In this 
experiment, he treatment did not affect FDG uptake or 
viability at least until the termination of the PET scanning. 
Corresponding to the result of in vitro study, TPA treat- 
ment augmented the accumulation of RAW117-P cells in 
the liver. Fig. 5 shows the time-activity curve of the liver 
accumulation of these cells. TPA treatment augmented the 
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Fig. 5. T ime-act iv i ty  curves  of  USF accumulat ion  in the l iver after 
inject ion o f  [2-nSF]FDG-labeled RAWl l7 -P  cells treated or not with 
TPA.  T ime-act iv i ty  curves  o f  18F in the l iver after injection o f  [2- 
]SF]FDG- labeled RAWl l7 -P  treated (0 )  or not (C))  with TPA were 
obtained as descr ibed in Mater ia ls  and methods.  
accumulation of the cells in the liver from right after the 
injection to the end of the scanning period. 
In contrast o the TPA treatment of the RAW ll7-P 
cells, Fig. 6 shows the suppression of the hepatic accumu- 
lation of RAWl l7-HI0 by the treatment with H-7, an 
inhibitor of PKC. The suppression, however, occurred only 
right after injection of the cells. This is obvious by the 
time-activity curve shown in Fig. 7, where the suppression 
of the accumulation of H-7-treated cells was observed only 
during the first 30 min after injection of the cells. Such a 
phenomenon could not have been detected before the 
non-invasive method for analyzing real-time cell traffick- 
ing was developed. In this experiment, H-7-treatment did 
not affect FDG uptake or viability at least until the termi- 
nation of the PET scanning. 
4. Discussion 
Metastasis occurs via a series of sequential steps [16,17]. 
Especially, in the organ-specific metastases, tumor cell 
adhesion to the venular endothelium of the target organ is 
thought o serve as an essential step after the detachment 
from the primary tumor sites and dissemination through 
the circulatory system [18]. Recent studies have indicated 
that the adhesion molecules of both tumor cells and en- 
dothelial cells of target organs play an important role in 
organ-specific metastases [19-24]. 
Positron emission tomography (PET) using [2-~8F]FDG 
has been applied to cancer diagnosis, based on the higher 
metabolic demand of tumor cells than of non malignant 
cells this positron-labeled compound [25-27]. In the pre- 
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Fig. 7. Time-activity curves of 18F accumulation in the liver after 
injection of [2-18 F]FDG-labeled RAW117-H10 ceils treated or not with 
H-7. Time-activity curves of ~8F in the liver after injection of [2- 
18F]FDG-labeled RAW117-H10 treated (• )  or not (D)  with H-7 were 
obtained as described in Materials and methods. 
sent study, we used FDG as a simple labeling agent of 
metastatic tumor cells. Thus PET could detect real-time 
cell trafficking in vivo. When we examined the trafficking 
of RAW 117 large cell lymphomas with different metastatic 
potential, i.e., parental RAW117-P and the highly liver 
metastatic subline RAWll7-H10, we observed that the 
subline cells tended to accumulate more in the liver than 
the parental, although the accumulation of both types of 
cell in the lungs was more intense than that in the liver due 
to the passage of the cells through this organ first after i.v. 
injection. 
Previous observations suggested that the reason for the 
higher metastatic potential of RAW117-H10 for the liver 
than that of parental RAW117-P is due to (1) the higher 
adhesiveness of RAW117-H10 to hepatic sinusoidal mi- 
crovessel endothelium (HSE) [28], (2) deletion of mem- 
brane markers important for macrophage-mediated cytosta- 
sis [29], or (3) the softness of RAW117-H10 cell mem- 
brane which may cause the higher deformability in narrow 
vessels [30]. Against the first reason, a study involving the 
determination of cells accumulated in removed organs 
showed no correlation between accumulation of cells in 
vivo and metastatic potential [31]. On the contrary, the 
non-invasive PET study presented here indicated that the 
actual accumulation of metastatic cells in the target organ 
could be correlated with the metastatic potential and with 
the adhesiveness in vitro toward HSE. This discrepancy 
occurred because our experimental system can detect the 
rather weaker adhesion in vivo that can not be detected by 
invasive methods uch as removal of organs. 
Furthermore, the correlation between adhesion proper- 
ties and in vivo trafficking was confirmed by the modula- 
tion of PKC, which affected adhesion of RAW117 
Thus, PKC activation by TPA treatment of RAWll7-P 
cells increased the degree of adhesion of the cells to HSE 
in vitro. Also, a greater accumulation of these cells in the 
liver was seen in vivo. On the contrary, PKC inactivation 
of RAW117-HI0 by H-7 suppressed both in vitro adhesion 
and in vivo accumulation of the cells in the liver. The 
suppression of H-7-treated RAW 117-H 10 accumulation i
liver was observed only during the first 30 min after 
administration of the cells. The reason that suppression did 
not last for long time is not clear at present. One possibil- 
ity is that the adhesion molecules which are not regulated 
by PKC activity play a role at the later stage of PET 
scanning. 
Although the correlation between metastatic behavior 
and adhesiveness of tumor cells is not fully understood, 
and although several different determinants on cell sur- 
faces may be involved in these processes, our data clearly 
indicate that the adhesiveness of RAW117 cells to HSE in 
vitro is critical for the trafficking of these cells in vivo. 
Several previous reports have indicated an effect of 
PKC modulation on metastasis: the adhesion rate of tumor 
cells to capillary endothelial cells is reported to be en- 
hanced by phorbol esters through enhancement of their 
binding capacity without affecting their affinity for the 
endothelium [32]. Conformational changes of adhesion 
molecules induced by the phosphorylation may affect their 
binding characteristics for their ligands [33]. Especially, 
integrins, which may play an important role in the binding 
of the metastatic tumor cell to endothelium, have been 
shown to be substrates for PKC [34,35]. PKC is also 
reported to be involved in signal transduction of TNF in a 
number of types of tumor cells including lymphoid cell 
lines, where TNF caused a transient activation and translo- 
cation of PKC [36]. A number of studies demonstrated that 
PKC plays a critical role in metastatic cell behavior [4,9,11]. 
The present study clearly demonstrates that the modulation 
of PKC influenced the in vivo trafficking of metastatic 
tumor cells. The trafficking of tumor cells may be affected 
by other factors that are not assessable in simple in vitro 
adhesion assay systems. For example, LPS, IL-1/3 and 
IFN-y are potent inducers of cell adhesion. These 
molecules enhance cell binding by altering the endothelial 
cell-adhesive properties without having direct effects on 
tumor cells [37-39]. 
In conclusion, the adhesion properties of metastatic 
ceils may be of critical importance for in vivo accumula- 
tion of the cells in the target organ, although the differen- 
tial accumulation of cells of high and low metastatic 
potential could be detected only by the non-invasive method 
since a subtle difference in initial binding of metastatic 
cells to the endothelium ay not be determined ue to the 
bulk dissociation of weakly bound cells during the deter- 
mination by the invasive method. The PET technique 
presented here may also clarify the determinant surface 
molecules through monitoring of overall in vivo trafficking 
of tumor cells. 
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